Paul Workman

Chief Executive and President of The Institute of Cancer Research.

Professor Paul Workman FMedSci, FRS is Chief Executive and President of The Institute of Cancer Research (ICR). 

Professor Workman is a passionate advocate of personalised molecular medicine and is an enthusiastic practitioner of multidisciplinary cancer drug discovery and development approaches to 'drugging the cancer genome'. He also conceptualised the 'Pharmacological Audit Trail' approach.

Visit website:

See also: Academia Institute of Cancer Research

Paul Workman News

Clinical trials now up for Exscientia's world first AI-made drug

pharmaphorum - 30-Jan-2020

Partnering with Japan's DSP, a milestone is reached in OCD treatment


Drug molecule developed using AI to undergo human trials

BBC - 30-Jan-2020

Can speed up drug discovery process using artificial intelligence


An effective immunotherapy for advanced prostate cancer

BBC - 28-Nov-2019

Only 5% saw their tumours shrink, but may be more successful if used earlier


Pembrolizumab: effective immunotherapy for advanced head and neck cancer

BBC - 23-Nov-2019

Needs to identify those who will respond to treatment before starting immunotherapy


Discovering the structure of cancer molecule can be the key for new treatment

Medical News Today - 16-Sep-2019

By determining the DHX8's structure, scientists could discover new ways of cancer treatment